

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

NCT06607627

Status	RECRUITING
Phase	Phase 3
Sponsor	Alexion Pharmaceuticals, Inc.
Enrollment	12 participants

Key Eligibility Criteria

Inclusion (7)

- United States of America (USA) specific inclusion criterion:
 - Participant must be 12 to < 18 years of age at the time of signing the informed consent/assent.
 - All participants must be vaccinated against meningococcal infection from serogroups A, B, C, W, and Y within 3 years and at least 2 weeks prior to the first dose of study intervention administration.
 - Participant must be 6 to < 18 years of age at the time of signing the informed consent/assent.
 - All participants must be vaccinated against meningococcal infection from serogroups A, C, W, Y (and B where available) within 3 years prior to study intervention on Day 1. If vaccination occurs < 2 weeks prior to Day 1, the participants will receive prophylactic antibiotics for at least 2 weeks after initial meningococcal vaccination for serogroups A,C,W,Y (and B, where available)
- ... and 2 more (see full listing online)

Exclusion (4)

- History of thymectomy, or any other thymic surgery within 12 months prior to Screening
- Untreated thymic malignancy, carcinoma, or thymoma
- History of Neisseria meningitidis infection
- Pregnancy, breastfeeding, or intention to conceive during the course of the study

Locations (13 total)

Research Site, Washington D.C., District of Columbia, United States
Research Site, Norfolk, Virginia, United States
Research Site, Joinville, Brazil
... and 10 more locations

<https://clinicaltrials.gov/study/NCT06607627>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.